EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Designing an mRNA Vaccine against P. jirovecii Involved in Fatal Pneumonia Infections via Comparative Proteomics and Reverse Vaccinology Approaches

Muhammad Naveed, Khizra Jabeen, Tariq Aziz, Muhammad Saad Mughal, Hammad Arif, Metab Alharbi, Thamer H Albakeiri, Abdullah F Alasmari

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2907246 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Muhammad Naveed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, 54590 Lahore, Pakistan. Hauptthemen laut MEDLINE: Proteomics, Pneumocystis carinii, Vaccinology, mRNA Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pneumocystis jirovecii is the most emerging life-threating health problem that causes acute and fatal pneumonia infection. It is rare and more contagious for patients with leukemia and immune-deficiency disorders. Until now there is no treatment available for this infection therefore, it is needed to develop any treatment against this pathogen.

Methods

In this work, we used comparative proteomics, robust immune-informatics, and reverse vaccinology to create an mRNA vaccine against Pneumocystis jirovecii by targeting outer and transmembrane proteins. Using a comparative subtractive proteomic analysis of two Pneumocystis jirovecii proteomes, a distinct non-redundant Pneumocystis jirovecii (strain SE8) proteome was chosen. Seven Pneumocystis jirovecii transmembrane proteins were chosen from this proteome based on hydrophilicity, essentiality, virulence, antigenicity, pathway interaction, protein-protein network analysis, and allergenicity.

Objective

The reverse vaccinology approach was used to predict the immunogenic and antigenic epitopes of major histocompatibility complex (MHC) I, II and B-cells from the selected proteins on the basis of their antigenicity, toxicity and allergenicity. These immunogenic epitopes were linked together to construct the mRNA-based vaccine. To enhance the immunogenicity, suitable adjuvant, linkers (GPGPG, KK, and CYY), and PRDRE sequences were used.

Results

Through predictive modeling and confirmation via the Ramachandran plot, we assessed secondary and 3D structures. The adjuvant RpfE was incorporated to enhance the vaccine construct’s immunogenicity (GRAVY index: –0.271, instability index: 39.53, antigenicity: 1.0428). The physiochemical profiling of vaccine construct was predicted it an antigenic, efficient, and potential vaccine. Notably, strong interactions were observed between the vaccine construct and TLR-3/TLR-4 (–1301.7 kcal/mol-1 and –1374.7 kcal/mol-1).

Conclusions

The results predicted that mRNA-based vaccines trigger a cellular and humoral immune response, making the vaccine potential candidate against Pneumocystis jirovecii and it is more suitable for in-vitro analysis and validation to prove its effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsPneumocystis cariniiVaccinologymRNA VaccinesPneumonia, PneumocystisHumansFungal VaccinesFungal ProteinsProteomeRNA, MessengerVaccine DevelopmentVaccines, Synthetic

Stichwörter der Autor:innen

immune-deficiencyin-vitromRNApathwayprofilingproteomereverse vaccinologytransmembrane

Substanzen

mRNA VaccinesFungal VaccinesFungal ProteinsProteomeRNA, MessengerVaccines, Synthetic

Autor:innen und Institutionen

  • Department of Biotechnology, Faculty of Science and Technology, University of Central Punjab, 54590 Lahore, Pakistan.
  • Department of Agriculture University of Ioannina, 47100 Arta, Greece.
  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, 11451 Riyadh, Saudi Arabia.

Förderung

  • King Saud University

Zitieren

APA

Naveed, M., Jabeen, K., Aziz, T., Mughal, M. S., Arif, H., Alharbi, M., Albakeiri, T. H., & Alasmari, A. F. (2024). Designing an mRNA Vaccine against P. jirovecii Involved in Fatal Pneumonia Infections via Comparative Proteomics and Reverse Vaccinology Approaches. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2907246

Vancouver

Naveed M, Jabeen K, Aziz T, Mughal MS, Arif H, Alharbi M, et al. Designing an mRNA Vaccine against P. jirovecii Involved in Fatal Pneumonia Infections via Comparative Proteomics and Reverse Vaccinology Approaches. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2907246

BibTeX
@article{Naveed2024,
  author = {Naveed, Muhammad and Jabeen, Khizra and Aziz, Tariq and Mughal, Muhammad Saad and Arif, Hammad and Alharbi, Metab and Albakeiri, Thamer H and Alasmari, Abdullah F},
  title = {Designing an mRNA Vaccine against P. jirovecii Involved in Fatal Pneumonia Infections via Comparative Proteomics and Reverse Vaccinology Approaches},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2907246}
}
Kostenlos starten →